Table 1.
Demographic and clinical details of the external dataset
| Total (n = 143) | |
|---|---|
| Males (n [%]) | 126 [88%] |
| Age (years) | 62 [23–86] |
| Weight (kg) | 104 [64–177] |
| European (n [%]) | 70 [49%] |
| Pacific Island (n [%]) | 39 [27%] |
| Māori (n [%]) | 27 [19%] |
| South Asian (n [%]) a | 4 [3%] |
| East Asian (n [%]) | 3 [2%] |
| CLcr (ml min −1 ) b | 61 [11–150] |
| Diuretics (n [%]) c | 53 [37%] |
| Beta‐blockers (n [%]) | 60 [42%] |
| Angiotensin converting enzyme inhibitors (n [%]) | 78 [55%] |
| Angiotensin II receptor blockers (n [%]) | 17 [12%] |
| Calcium channel blockers (n [%]) | 33 [23%] |
| HMG‐CoA reductase inhibitor (n [%]) | 75 [52%] |
| Uricosuric (n [%]) | 5 [3.5%] |
| Allopurinol dose at target SU (mg day −1 ) | 350 [100–700] |
| Oxypurinol at target SU (μmol l −1 ) d | 105 [30–512] |
| Pretreatment urate (mmol l −1 ) e | 0.61 [0.36–0.89] |
| Urate at target (mmol l −1 ) | 5.4 [3.5–6.0] |
All data expressed as median [range] unless otherwise stated. CLcr = creatinine clearance.
Subjects of Southern Asian ancestry were all Indian.
Creatinine clearance determined using the Cockcroft‐Gault equation 17.
Diuretics included n = 40 loop (39 × frusemide, 1 × bumetanide), n = 13 thiazides (10 × hydrochlorothiazide, 3 × bendrofluazide) and n = 1 spironolactone.
Oxypurinol plasma concentrations were measured for 110 individuals.
Pretreatment urate concentrations were available for 53 individuals.